Search
Call for interest
As a member of an EHA committee or taskforce, you’ll be instrumental in taking our ambitions to the next level.
Read moreEHA Innovation Grant review and selection process
1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.
Read moreEHA Mentorship Program eligibility
Before applying for the EHA Mentorship Program, please consider the eligibility criteria on this page. You should also read our policy on life events.
Read moreGrants & abstract awards
EHA Travel GrantsThe call for travel grant applications will be open from January 1, 2025 until March 1, 2025 (23:59 CET). New: Grant applications have been integrated into the EHA2025 Abstract Submission form.
Read moreScam alert
Beware of unauthorized or fraudulent hotel and registration booking agencies. INTERPLAN AG is the official housing bureau for the EHA2025 Congress.
Read moreBoard elections
Shape the future of EHA by taking part in our 2025 Board election. Nominations close at 23:59 (CET) on February 9, 2025.
Read moreCongratulations to the 2021 Research Grant winners!
The Hague, 2 June 2021 –EHA congratulates nine talented researchers in hematology on their receipt of the EHA Research Grants 2021 after a rigorous selection process.
Read moreHematology 2.0: navigating the world of medical apps
Interview with Dr Alex Langridge, SpR, by Dr Nuno Borges, MBBS, MRes, on behalf of YoungEHA. Despite the controversy surrounding them, medical apps remain extremely popular and lucrative endeavors.
Read morePublications
Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD. Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, García EM, Sánchez-Guijo F, Argüeso P, Aijón J, Hernández-Galilea E, Velasco A. Ocul Surf. 2019 Jan 7.
Read moreSelected EMA news
December 2024New information on approved medicines
Sarclisa (isatuximab) - new indication
Treatment of multiple myeloma (a type of blood cancer)
Withdrawal of applications for extension of indication
Inaqovi (cedazuridine / decitabine)
Treatment of different types of blood cancer
Direct Healthcare Professional Communication (DHPC)
Pegasys (peginterferon alfa-2a)
Treatment of…